Skip to main content
. 2017 Mar 9;8(20):33002–33013. doi: 10.18632/oncotarget.16031

Figure 1.

Figure 1

(A) shows the relationship between IKKβ expression and cancer-specific survival in patients with primary operable invasive ductal breast cancer (P=0.903). (B) shows the relationship between cytoplasmic p-p65 expression and cancer-specific survival in patients with primary operable invasive ductal breast cancer (P=0.052). (C) shows the relationship between nuclear p-p65 expression and cancer-specific survival in patients with invasive ductal breast cancer (P=0.042). (D) shows the relationship between nuclear p-p65 expression and cancer-specific survival in patients with Luminal A invasive ductal breast cancer (P=0.972). (E) shows the relationship between nuclear p-p65 expression and cancer-specific survival in patients with Luminal B invasive ductal breast cancer (P=0.018). (F) shows the relationship between nuclear p-p65 expression and cancer-specific survival in patients with triple negative invasive ductal breast cancer (P=0.120). (G) shows the relationship between nuclear p-p65 expression and cancer-specific survival in patients with HER2 enriched invasive ductal breast cancer (P=0.868).